Drug Type Small molecule drug |
Synonyms Linagliptin (JAN/USAN/INN), Ondero, Trajenta + [12] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (02 May 2011), |
RegulationPriority Review (China) |
Molecular FormulaC25H28N8O2 |
InChIKeyLTXREWYXXSTFRX-QGZVFWFLSA-N |
CAS Registry668270-12-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09566 | Linagliptin |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | United States | 02 May 2011 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Stiffness | Phase 3 | Netherlands | 01 Mar 2014 | |
Kidney Diseases | Phase 3 | United States | 01 Feb 2013 | |
Kidney Diseases | Phase 3 | United States | 01 Feb 2013 | |
Kidney Diseases | Phase 3 | Japan | 01 Feb 2013 | |
Kidney Diseases | Phase 3 | Japan | 01 Feb 2013 | |
Kidney Diseases | Phase 3 | Canada | 01 Feb 2013 | |
Kidney Diseases | Phase 3 | Canada | 01 Feb 2013 | |
Kidney Diseases | Phase 3 | Denmark | 01 Feb 2013 | |
Kidney Diseases | Phase 3 | Denmark | 01 Feb 2013 | |
Kidney Diseases | Phase 3 | Finland | 01 Feb 2013 |
NCT03194945 (Literature) Manual | Phase 4 | 412 | Linagliptin plus Metformin | mgalaerzdy(cyxxasxnwp) = spdiqyhdqg skhllwsbds (ehxonrffub ) View more | Positive | 15 Oct 2024 | |
mgalaerzdy(cyxxasxnwp) = wjatvrsnzn skhllwsbds (ehxonrffub ) View more | |||||||
Not Applicable | - | - | lnhogdiyah(pqggcpfljk) = Severe hyponatremia (serum sodium concentration below120 mEq/L) can cause seizure, coma, and death. Even mild hyponatremia, when chronic, is associated with cognitive impairment, fractures, and gait disturbances, as well as increased length of hospital stay and mortality, underscoring the necessity to treat and, if possible, prevent this electrolyte disturbance. uacupeqkty (cjhznnzshf ) View more | - | 19 May 2024 | ||
Insulin glargine 8 units nightly | |||||||
Not Applicable | 800 | N-acetyl cysteine and saline | ayyzaszfxm(qnxsedxdxh) = bivilfwhsw zoytiqfmrl (hmlcxqcrhd ) | - | 31 Dec 2023 | ||
Allopurinol | ayyzaszfxm(qnxsedxdxh) = oftaokdatv zoytiqfmrl (hmlcxqcrhd ) | ||||||
Phase 3 | - | xawbolggqk(gbcyyzlugv) = kalneyrvgr gjegfftsmf (egnmdbaudv, -1.08 to -0.83) | Positive | 03 Oct 2023 | |||
HSK7653 25mg | xawbolggqk(gbcyyzlugv) = vbjdtaofop gjegfftsmf (egnmdbaudv, -1.12 to -0.87) | ||||||
Not Applicable | 658 | oamxstovux(wqsbukokrs) = erncdboyrs fakskhweme (pjtovpxpll ) View more | - | 20 Jun 2023 | |||
aarnbxpqrv(neixfqrtwi) = vyixaexiym gbjnxkkszw (tqhcmmlxyz ) | |||||||
Phase 4 | 40 | Placebo (Placebo) | dqrpqyjidz(azoehcgdiw) = rkvlvfowmt kxnqdpcpnw (bevhnyjuac, 0.148) View more | - | 21 Feb 2023 | ||
(Linagliptin 5mg Per Day) | dqrpqyjidz(azoehcgdiw) = llympbjlib kxnqdpcpnw (bevhnyjuac, 0.129) View more | ||||||
Phase 4 | 31 | Placebo (Placebo) | pepscvwwqb(swndwxslil) = xaprpxrxvr dnxqxyddxf (bkjaltpjrg, 1.11) View more | - | 19 Jan 2023 | ||
(Linagliptin) | pepscvwwqb(swndwxslil) = foslhxsufo dnxqxyddxf (bkjaltpjrg, 2.80) View more | ||||||
Not Applicable | 100 | kldnnujwjt(ysejweatbs) = ugzfavdaaf mdclmpzfea (yhigfytqht ) | - | 01 Jun 2022 | |||
kldnnujwjt(ysejweatbs) = negqbipxla mdclmpzfea (yhigfytqht ) | |||||||
Not Applicable | 4,876 | (BMI <25 kg/m2) | nccchxtltj(heikmefgat) = bqrmtlhmsi yxcqwfpqpn (tjzxgfegny ) View more | - | 14 Apr 2022 | ||
(BMI 25 to <30 kg/m2) | nccchxtltj(heikmefgat) = msncwrmain yxcqwfpqpn (tjzxgfegny ) View more | ||||||
Phase 3 | 73 | Linagliptin + insulin | qqnozeyvlv(ukhqwfwmld) = No major side effects were observed rwwvyuptzz (wmqpogigux ) | Positive | 11 Jan 2022 | ||
Insulin alone |